grant
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics
Organization SOUTHERN METHODIST UNIVERSITYLocation DALLAS, UNITED STATESPosted 19 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025AcylationAddressAnabolismAnti Mycobacterial AgentsAnti-Bacterial AgentsAntibiotic AgentsAntibiotic DrugsAntibioticsAntimycobacterial AgentsAutoregulationBacteriaBioavailabilityBiochemicalBiochemistryBiologicalBiological AvailabilityBiological ChemistryBiologyBlood PlasmaCarbapenemsCcra beta-lactamaseCell WallChemicalsClinicalCrystallographiesCrystallographyCysteineDataDevelopmentDrug KineticsDrug PrecursorsDrugsEnzymatic BiochemistryEnzymologyEvaluationGeneticGenus MycobacteriumGoalsHalf-CystineHomeostasisHydrolysisIn VitroInfectionL-CysteineL-SerineLactam AntibioticsLactamaseLactamsLeadLibrariesM abscessusM avium ComplexM tbM tuberculosisM. abscessusM. avium ComplexM. avium intracellulareM. tbM. tuberculosisMAICMediatingMedicationMembrane TransportMeropenemMethodologyMicrobiologyMiscellaneous AntibioticModificationMonobactam AntibioticsMonobactamsMonocyclic beta-LactamsMureinMycobacterial InfectionMycobacteriumMycobacterium InfectionsMycobacterium abscessusMycobacterium avium ComplexMycobacterium avium-intracellulareMycobacterium avium-intracellulare ComplexMycobacterium tuberculosisMycobacteroides abscessusNTM infectionOralOutcomePatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPb elementPenicillin-Binding ProteinsPeptidoglycanPeptidyl TransferasesPeptidyl TranslocasesPeptidyltransferasePharmaceutical PreparationsPharmacokineticsPhysiologic AvailabilityPhysiological HomeostasisPlasmaPlasma SerumPositionPositioning AttributePredispositionPro-DrugsProdrugsPropertyProteinsQualifyingRegimenResearchResistanceReticuloendothelial System, Serum, PlasmaRoleSerineSpecificityStructure-Activity RelationshipSusceptibilitySynthesis ChemistrySynthetic ChemistryTB therapyTB treatmentTherapeuticTimeTransmembrane TransportTranspeptidasesTreatment ProtocolsTreatment RegimenTreatment ScheduleVDAC1VDAC1 geneanaloganti-bacterialanti-microbialantibiotic designantimicrobialantimycobacterialbiologicbiosynthesiscarbapenemasechemical structure functioncrosslinkdesigndesigningdevelopmentaldrug candidatedrug discoverydrug/agentheavy metal Pbheavy metal leadimprovedin vitro activityin vivoinhibitorinsightinterestlead optimizationmouse modelmtbmultidisciplinarymurine modelmycobacterialnon-tuberculosis mycobacterianon-tuberculosis mycobacterialnon-tuberculous mycobacterianon-tuberculous mycobacterialnon-tuberculous mycobacterial infectionnontuberculosis mycobacterialnontuberculous mycobacterianontuberculous mycobacterialnoveloperationoperationspathogenpatient oriented outcomespharmacologicpore forming proteinporinresistance strainresistantresistant strainscaffoldscaffoldingsocial rolestemstructural biologystructure function relationshiptherapeutic targettooltreat M. tuberculosistreat Mtbtreat Mycobacterium tuberculosistreat tbtreat tuberculosistuberculosis therapytuberculosis treatment
Description preview
Abstract
Mycobacterial infections, broadly including Mycobacterium tuberculosis (Mtb), and those caused by
nontuberculous mycobacteria (NTM) like the fast-growing Mycobacterium abscessus (Mab), as well as the slow-
growing Mycobacterium avium complex (MAC), represent some of the most clinically challenging and deadly
infections of the 21st…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click